On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Mark R. Litzow, MD, and William A. Wood, MD.

Question Title

* 1. Which of the following is a nonspecific manifestation of immune effector cell-associated neurotoxicity syndrome1 (ICANS) observed after chimeric antigen receptor (CAR) T cell therapy?

Question Title

* 2. Which of the following statements about encephalopathy assessment tools for grading of immune effector cell-associated neurotoxicity syndrome1 (ICANS) is CORRECT?

Question Title

* 3. FACT-JACIE Hematopoietic Cellular Therapy Accreditation Standards and Guidance3: The medical history of an allogeneic cellular therapy product donor must include all of the following EXCEPT

Question Title

* 4. All of the following are risk factors associated with ocular graft-versus-host disease EXCEPT?

Question Title

* 5. Which of the following statements about ocular graft-versus-host disease is CORRECT?

T